- Figure 3A: Serum neutralizing antibody titers
         - Similar to what was observed in Figure 1A vaccine + alum groups had 
            a higher geometric mean serum neutralizing antibody titer than those 
            without alum, but a dosage effect was not observed. 
         - BPV also differed by dosage with increasing dosages translating to 
            higher mean antibody titers. 
- Figure 3B: Lung viral titer
         - Aside from the 3 ug and 1 ug SV groups without alum, all groups had 
            negative viral cultures.


Serum neutralizing antibody titers & lung viral titer results at higher doses of SARS-CoV recombinant DNA spike (S) protein vaccine (SV)

- Figure 4A: Mean Lesion Score for Higher SV Doses and BPV Vaccine 
         - Scores were significantly lower in the SV groups compared to both 
            whole virus vaccines (DIV and BPV)
- Figure 4B: Mean Eosinophil Score among Higher SV Doses and BPV 
   Vaccine
         - Mean eosinophil scores were lower when comparing SV to DIV and 
            SV to BPV, however, all vaccine groups were greater than controls. 


Lung histology results at higher doses of SARS-CoV recombinant DNA spike (S) protein vaccine (SV)

- Serum Neutralizing Antibody Titers & Lung Viral Titer Results 
- Lung Histology Results 

University of Michigan - Ann Arbor

- Experiment 1: Comparisons of Vaccines
- Experiment 2: Assessment of higher doses of Recombinant DNA spike (S) protein vaccine (SV)
- Experiment 3: Mouse and Vaccine Specificity

Experiments Conducted in Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus

Tseng C, Sbrana E, Iwata-Yoshikawa N et al. Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus. PLoS ONE. 2012;7(4):e35421. doi:10.1371/journal.pone.0035421

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0035421

Learn Before

Related

Learn After